MCK
42
-8
ICE
66
-4
XEL
60
-5
FDX
37
-3
HES
49
-7
M
5
-3
SRCL
64
17
SRE
50
-7
PRGO
46
-4
HRL
36
3
C
47
-4
NVDA
38
-7
WAT
47
-2
AMG
30
-3
DE
46
8
GOOGL
39
-8
MCO
73
-5
AIG
39
-9
THC
55
-7
DNB
58
4
MCK
42
-8
ICE
66
-4
XEL
60
-5
FDX
37
-3
HES
49
-7
M
5
-3
SRCL
64
17
SRE
50
-7
PRGO
46
-4
HRL
36
3
C
47
-4
NVDA
38
-7
WAT
47
-2
AMG
30
-3
DE
46
8
GOOGL
39
-8
MCO
73
-5
AIG
39
-9
THC
55
-7
DNB
58
4
Financhill
Back

Janux Therapeutics 10K Form

Sell
34

JANX
Janux Therapeutics

Last Price:
41.31
Seasonality Move:
-14.57%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive JANX News And Ratings

See the #1 stock for the next 7 days that we like better than JANX

JANX Financial Statistics

Sales & Book Value

Annual Sales: $8.08M
Cash Flow: $-10.12M
Price / Cash Flow: 0
Annual Sales: $12.61
Price / Book: 3.27

Profitability

EPS (TTM): -0.90000
Net Income (TTM): $-44.05M
Gross Margin: --
Return on Equity: -9.55%
Return on Assets: -8.85%

Janux Therapeutics Earnings Forecast

Key Janux Therapeutics Financial Ratios

  • The Research & Development expenses have been 679.48% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of JANX is -721.18% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 2 years.

Janux Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: JANX
Website: januxrx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 57.34
Quick Ratio: 57.02

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

JANX Technical Analysis vs Fundamental Analysis

Sell
34
Janux Therapeutics (JANX) is a Sell

Is Janux Therapeutics a Buy or a Sell?